148 related articles for article (PubMed ID: 38130950)
21. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease.
Magno P; Jiménez CE; Ortiz Z; Torres EA
P R Health Sci J; 2010 Mar; 29(1):60-5. PubMed ID: 20222336
[TBL] [Abstract][Full Text] [Related]
22. Correction to: Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Inflamm Bowel Dis; 2023 Dec; 29(12):2011-2012. PubMed ID: 37877812
[No Abstract] [Full Text] [Related]
23. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
24. A Multi-Disciplinary Approach to Perianal Fistulizing Crohn's Disease.
Wiseman J; Chawla T; Morin F; de Buck van Overstraeten A; Weizman AV
Clin Colon Rectal Surg; 2022 Jan; 35(1):51-57. PubMed ID: 35069030
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of Crohn's disease treated with infliximab.
Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
[TBL] [Abstract][Full Text] [Related]
26. A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease.
Lightner AL; Otero-Pineiro A; Reese J; Ream J; Nachand D; Adams AC; VanDenBossche A; Kurowski JA
Inflamm Bowel Dis; 2023 Dec; 29(12):1912-1919. PubMed ID: 37263018
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.
Lee MJ; Parker CE; Taylor SR; Guizzetti L; Feagan BG; Lobo AJ; Jairath V
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1879-1892. PubMed ID: 29374617
[TBL] [Abstract][Full Text] [Related]
28. Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.
Garcia-Olmo D; Gilaberte I; Binek M; D Hoore AJL; Lindner D; Selvaggi F; Spinelli A; Panés J
Dis Colon Rectum; 2022 May; 65(5):713-720. PubMed ID: 34890373
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
30. Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch.
Shen B; Fazio VW; Remzi FH; Bennett AE; Lavery IC; Lopez R; Brezinski A; Sherman KK; Bambrick ML; Lashner BA
Dis Colon Rectum; 2007 Sep; 50(9):1450-9. PubMed ID: 17665259
[TBL] [Abstract][Full Text] [Related]
31. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.
Ford AC; Luthra P; Hanauer SB; Travis SP; Harris MS; Reinisch W
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):1981-90. PubMed ID: 25218669
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
33. Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.
Ayoub F; Odenwald M; Micic D; Dalal SR; Pekow J; Cohen RD; Rubin DT; Sakuraba A
Intest Res; 2022 Apr; 20(2):240-250. PubMed ID: 35124951
[TBL] [Abstract][Full Text] [Related]
34. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of FiLaC™ for perianal fistulizing Crohn's disease: a systematic review and meta-analysis.
Cao D; Li W; Ji Y; Wang X; Cui Z
Tech Coloproctol; 2022 Oct; 26(10):775-781. PubMed ID: 35962294
[TBL] [Abstract][Full Text] [Related]
36. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
[TBL] [Abstract][Full Text] [Related]
37. A Phase IB/IIA Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease.
Lightner AL; Reese J; Ream J; Nachand D; Jia X; Dadgar N; Steele SR; Hull T
Dis Colon Rectum; 2023 Oct; 66(10):1359-1372. PubMed ID: 36602511
[TBL] [Abstract][Full Text] [Related]
38. Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease.
Sordo-Mejia R; Gaertner WB
World J Gastrointest Pathophysiol; 2014 Aug; 5(3):239-51. PubMed ID: 25133026
[TBL] [Abstract][Full Text] [Related]
39. Crohn's of the Pouch: Now What?
Connelly TM; Lincango E; Holubar SD
Clin Colon Rectal Surg; 2022 Nov; 35(6):475-486. PubMed ID: 36591396
[TBL] [Abstract][Full Text] [Related]
40. Response to infliximab is related to disease duration in paediatric Crohn's disease.
Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
